CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: The phenotype of anti-PR1 was enriched to CD8 + TEM/EMRA cells (odds-ratio OR 43.134), which were enriched in patients with CML before TKI treatment in comparison to healthy and other cancers (median 20.2% vs 5.37%, log2FC = 1.911, P = 0.0082, two-sided Mann-Whitney test, Fig. 6a, b).